NASDAQ:GRCL Gracell Biotechnologies (GRCL) Stock Price, News & Analysis → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Free GRCL Stock Alerts $10.25 +0.01 (+0.10%) (As of 02/22/2024) Add Compare Share Share Today's Range$10.17▼$10.2850-Day Range$9.99▼$10.3552-Week Range$1.40▼$10.44Volume6.42 million shsAverage Volume1.32 million shsMarket Capitalization$744.95 millionP/E RatioN/ADividend YieldN/APrice Target$13.04 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Gracell Biotechnologies alerts: Email Address Ad Porter & CompanyAI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. About Gracell Biotechnologies Stock (NASDAQ:GRCL)Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited.Read More GRCL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GRCL Stock News HeadlinesMarch 3, 2024 | finance.yahoo.comGRCL Mar 2024 10.000 call(CONTRFebruary 22, 2024 | finance.yahoo.comGracell Biotechnologies Acquisition CompletedMarch 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.February 22, 2024 | globenewswire.comGracell Biotechnologies Acquisition CompletedFebruary 21, 2024 | seekingalpha.comAstraZeneca Deal For Gracell Biotechnologies Closing Tomorrow (Includes CVR)February 21, 2024 | investing.comGracell Biotechnologies Inc. (GRCL)February 20, 2024 | finanznachrichten.deGracell Biotechnologies Inc.: Gracell Biotechnologies Announces Shareholders' Approval of Merger AgreementFebruary 20, 2024 | finance.yahoo.comGracell Biotechnologies Announces Shareholders’ Approval of Merger AgreementMarch 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.February 20, 2024 | globenewswire.comGracell Biotechnologies Announces Shareholders' Approval of Merger AgreementFebruary 17, 2024 | finance.yahoo.comGRCL Mar 2024 2.500 callFebruary 17, 2024 | seekingalpha.comGRCL Gracell Biotechnologies Inc.January 29, 2024 | finance.yahoo.comGracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple MyelomaJanuary 3, 2024 | finance.yahoo.comGracell Biotechnologies Inc. Sponsored ADR (GRCL) is a Great Momentum Stock: Should You Buy?December 31, 2023 | businesswire.comGRACELL BIOTECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ...December 27, 2023 | markets.businessinsider.comMaintaining Hold on Gracell Biotechnologies Amidst AstraZeneca Acquisition ProspectsDecember 26, 2023 | msn.comWhy China-Based Gracell Biotechnologies (GRCL) Stock Is Soaring TodayDecember 26, 2023 | finance.yahoo.comGracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseasesDecember 26, 2023 | markets.businessinsider.comGracell Biotechnologies, Stratasys, Hollysys Automation Technologies And Other Big Stocks Moving Higher In Tuesday's Pre-Market SessionDecember 26, 2023 | tmcnet.comGRCL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Gracell Biotechnologies Inc. Is Fair to ShareholdersDecember 21, 2023 | finance.yahoo.comGracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus ErythematosusDecember 21, 2023 | finance.yahoo.comGracell Biotechnologies Inc. Sponsored ADR (GRCL) Is a Great Choice for 'Trend' Investors, Here's WhyDecember 12, 2023 | finance.yahoo.comGracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023December 11, 2023 | finance.yahoo.comWall Street Analysts Believe Gracell Biotechnologies Inc. Sponsored ADR (GRCL) Could Rally 127.82%: Here's is How to TradeDecember 2, 2023 | finance.yahoo.comInstitutions own 19% of Gracell Biotechnologies Inc. (NASDAQ:GRCL) shares but private equity firms control 45% of the companyNovember 29, 2023 | markets.businessinsider.comBuy Rating for Gracell Biotechnologies on Promising CAR-T Cell Therapy AdvancementsNovember 28, 2023 | msn.comEvercore ISI Group Initiates Coverage of Gracell Biotechnologies Inc - ADR (GRCL) with Outperform RecommendationSee More Headlines Receive GRCL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gracell Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2021Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:GRCL CUSIPN/A CIK1826492 Webwww.gracellbio.com Phone86-512-6262-6701FaxN/AEmployees314Year FoundedN/APrice Target and Rating Average Stock Price Target$13.04 High Stock Price Target$20.00 Low Stock Price Target$10.00 Potential Upside/Downside+27.2%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-88,080,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-37.40% Return on Assets-31.24% Debt Debt-to-Equity Ratio0.02 Current Ratio7.73 Quick Ratio7.73 Sales & Book Value Annual Sales$60,000.00 Price / Sales12,415.83 Cash FlowN/A Price / Cash FlowN/A Book Value$2.95 per share Price / Book3.47Miscellaneous Outstanding Shares72,678,000Free Float52,328,000Market Cap$744.95 million OptionableOptionable Beta-0.33 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Wei Cao BM (Age 65)Ph.D., Founder, Chairman & CEO Dr. Yili Xie M.B.A. (Age 53)Ph.D., Chief Financial Officer Dr. Samuel Suhua Zhang M.B.A. (Age 56)Ph.D., Chief Business Officer Dr. Wendy Li M.D. (Age 65)Chief Medical Officer Ms. Erin LiExecutive OfficerKey CompetitorsIcosavaxNASDAQ:ICVXFate TherapeuticsNASDAQ:FATEVoyager TherapeuticsNASDAQ:VYGRHarpoon TherapeuticsNASDAQ:HARPPoseida TherapeuticsNASDAQ:PSTXView All CompetitorsInstitutional OwnershipGoldman Sachs Group Inc.Bought 2,132 shares on 3/1/2024Ownership: 0.025%Virtu Financial LLCBought 10,896 shares on 2/26/2024Ownership: 0.015%Prelude Capital Management LLCBought 24,647 shares on 2/15/2024Ownership: 0.056%GTS Securities LLCBought 25,144 shares on 2/15/2024Ownership: 0.035%Citadel Advisors LLCBought 6,600 shares on 2/15/2024Ownership: 0.000%View All Institutional Transactions GRCL Stock Analysis - Frequently Asked Questions Should I buy or sell Gracell Biotechnologies stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gracell Biotechnologies in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GRCL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GRCL, but not buy additional shares or sell existing shares. View GRCL analyst ratings or view top-rated stocks. What is Gracell Biotechnologies' stock price target for 2024? 8 Wall Street research analysts have issued 1 year target prices for Gracell Biotechnologies' shares. Their GRCL share price targets range from $10.00 to $20.00. On average, they predict the company's stock price to reach $13.04 in the next twelve months. This suggests a possible upside of 27.2% from the stock's current price. View analysts price targets for GRCL or view top-rated stocks among Wall Street analysts. How have GRCL shares performed in 2024? Gracell Biotechnologies' stock was trading at $10.04 at the start of the year. Since then, GRCL stock has increased by 2.1% and is now trading at $10.25. View the best growth stocks for 2024 here. How were Gracell Biotechnologies' earnings last quarter? Gracell Biotechnologies Inc. (NASDAQ:GRCL) released its quarterly earnings data on Sunday, November, 14th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.18. The business earned $0.06 million during the quarter. When did Gracell Biotechnologies IPO? Gracell Biotechnologies (GRCL) raised $150 million in an IPO on Friday, January 8th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Citigroup, Jefferies, Piper Sandler and Wells Fargo Securities acted as the underwriters for the IPO. Who are Gracell Biotechnologies' major shareholders? Gracell Biotechnologies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vivo Capital LLC (13.13%), TIG Advisors LLC (1.76%), Alpine Associates Management Inc. (1.76%), Octagon Capital Advisors LP (0.82%), Sphera Funds Management LTD. (0.69%) and MMCAP International Inc. SPC (0.62%). How do I buy shares of Gracell Biotechnologies? Shares of GRCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GRCL) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gracell Biotechnologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.